Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab

20Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVE: To describe the disease course of carryover progressive multifocal leukoencephalopathy (PML) after switching from natalizumab to ocrelizumab in 2 patients with relapsing-remitting MS. METHODS: Two case reports with 1 year of follow-up and retrospective longitudinal measurements of serum neurofilament light (NfL) levels and B-cells. RESULTS: PML was diagnosed 78 days (case 1) and 97 days (case 2) after discontinuation of natalizumab. Both patients developed mild immune reconstitution inflammatory syndrome (IRIS) despite B-cell depletion caused by ocrelizumab. NfL levels increased in both patients during PML-IRIS. PML-IRIS lesions stabilized after treatment with mefloquine and mirtazapine, followed by methylprednisolone, and both patients continued therapy with ocrelizumab when B-cells started to repopulate. CONCLUSIONS: The clinical course of carryover PML was mild in both patients, suggesting that B-cell depletion possibly did not aggravate PML-IRIS in these 2 patients.

Cited by Powered by Scopus

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis

50Citations
N/AReaders
Get full text

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

27Citations
N/AReaders
Get full text

The 2022 Lady Estelle Wolfson lectureship on neurofilaments

25Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Toorop, A. A., van Lierop, Z. Y. G., Strijbis, E. E. M., Teunissen, C. E., Petzold, A., Wattjes, M. P., … Killestein, J. (2021). Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Neurology(R) Neuroimmunology & Neuroinflammation, 8(1). https://doi.org/10.1212/NXI.0000000000000904

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

61%

Researcher 5

28%

Professor / Associate Prof. 2

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

50%

Neuroscience 9

41%

Agricultural and Biological Sciences 2

9%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 46

Save time finding and organizing research with Mendeley

Sign up for free